Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pacira BioSciences, Inc. (NASDAQ: PCRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Pacira is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its filings give detailed insight into how it manages product commercialization, manufacturing, financing and governance.
Pacira’s current reports on Form 8‑K cover topics such as quarterly financial results, workforce reductions tied to manufacturing efficiencies for EXPAREL, and a senior secured revolving credit facility used to refinance prior indebtedness and support working capital. One 8‑K describes the company’s investment in large-scale manufacturing suites in San Diego, California, and Swindon, United Kingdom, and the decision to decommission an earlier 45‑liter batch suite, while another outlines the terms of its credit agreement with lenders.
Investors reviewing Pacira’s filings typically focus on annual reports on Form 10‑K and quarterly reports on Form 10‑Q for information about its commercial products—EXPAREL, ZILRETTA and iovera°—and its clinical-stage gene therapy candidate PCRX-201. These filings generally discuss revenue composition, research and development activities, manufacturing capacity, risk factors and intellectual property, including patent protection for EXPAREL described in company press releases.
Forms 8‑K also document material events such as share repurchase authorizations, inducement equity grants under the company’s inducement plan, credit facility amendments and other significant corporate actions. For users interested in insider activity, Forms 3, 4 and 5 provide data on transactions by directors, officers and major shareholders, while proxy statements explain executive compensation and board matters.
On Stock Titan, AI-generated summaries help explain lengthy filings, highlight key changes from prior periods and surface items that may affect Pacira’s financial position or strategy. Real-time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and Form 4 filings for PCRX are quickly available, allowing investors to track developments in Pacira’s non-opioid pain portfolio, manufacturing initiatives and capital structure without reading every page manually.
Pacira BioSciences (PCRX): The Vanguard Group files Amendment No. 12 to Schedule 13G/A reporting zero beneficial ownership in Common Stock. The filing states 0 shares and 0% ownership and explains an internal realignment effective January 12, 2026 that produced disaggregated reporting by Vanguard subsidiaries. The filing is signed by Ashley Grim on 03/27/2026 and lists Vanguard's Malvern address.
Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. The grant was at no cash cost per share and increases his direct holdings to 31,065 common shares equivalents.
The units vest on June 11, 2026, only if he remains in continuous service with Pacira through that date. Each restricted stock unit converts into one share of Pacira common stock upon vesting, reflecting standard, service-based director compensation rather than an open-market purchase or sale.
Pacira BioSciences Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock in an open-market transaction at a price of $22.82 per share on March 17, 2026. After this sale, he directly holds 223,640.175 shares of Pacira common stock.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Slonin previously adopted, indicating the sale was scheduled in advance rather than timed discretionarily.
Pacira BioSciences, Inc. director Mark Froimson reported an open-market sale of 500 shares of common stock at $21.81 per share. After this transaction, he directly holds 20,136 shares. This filing reflects a relatively small sale compared with his remaining reported ownership.
PCRX files a Form 144 reporting proposed sale of Common Stock. The filing lists prior acquisitions of Common Stock: 209 shares purchased under an ESPP on 12/31/2021, 2,000 shares acquired on exercise of stock options on 05/23/2022, and 1,052 shares from restricted stock vesting on 06/03/2022. The notice identifies Fidelity Brokerage Services LLC as the broker.
Pacira BioSciences, Inc. is the target of an activist campaign by DOMA Perpetual Capital Management and affiliates, which report beneficial ownership of 2,936,794 common shares, or 7.3% of the company. The group, led by Pedro Escudero, filed Amendment No. 3 to Schedule 13D.
Using 40,489,894 shares outstanding as of February 23, 2026, DOMA and related entities disclose various stakes, including 4.9% held by Doma Perpetual LO Equity Master Fund and 2% reported for The John Templeton Foundation. On March 11, 2026, Doma Master Fund notified Pacira it intends to nominate three directors at the 2026 annual meeting and to solicit proxies.
In a March 12, 2026 press release incorporated in the filing, DOMA called for chief executive officer Frank Lee to be replaced and urged the board to appoint an interim CEO. DOMA also stated its view that Pacira’s stock price has declined over several years while expenses and management compensation have increased, and urged the board to run a formal sale process to maximize value for shareholders.
DOMA Perpetual announced a solicitation to nominate three director candidates to the board of Pacira BioSciences, Inc. and stated it beneficially owns approximately 7.3% of Pacira's common stock. The nominating group urges removal of CEO Frank Lee, requests an interim CEO and a formal sale process, and criticizes multi-year underperformance, management compensation changes to RSUs, and strategic decisions including relocation of headquarters. DOMA names nominees Christopher Dennis, Oliver Benton Curtis III and Eric de Armas, and says it will file a preliminary proxy statement and a WHITE universal proxy card to solicit votes at the 2026 annual meeting.
DOMA Perpetual is soliciting proxies to elect three nominees to the board of Pacira Biosciences and announced its intention to file a preliminary proxy statement and WHITE universal proxy card to be used at the 2026 annual meeting. In a Mar 11, 2026 press release, DOMA says it beneficially owns 7.1% of Pacira common stock and cites sustained underperformance, executive compensation concerns, and strategic disagreements.
DOMA requests the Board name an interim CEO, pursue a formal sale process for the company and replace CEO Frank Lee; it also nominates Christopher Dennis, Oliver Benton Curtis and Eric de Armas to address governance and strategic execution.
Pacira BioSciences provides a detailed update on its non-opioid pain franchise and growth strategy for the year ended December 31, 2025. EXPAREL remains the core product, with net product sales of $575.1 million, representing 79% of total revenue. ZILRETTA generated net product sales of $116.6 million and iovera° $24.2 million.
The company highlights its “5x30” plan to 2030, targeting double-digit product revenue growth, gross margin improvement and at least five clinical programs and five partnerships. It reports reaching 2.5 million patients in 2025 and adding strategic partnerships for EXPAREL and ZILRETTA.
Pacira expands on its pipeline, led by gene therapy candidate PCRX-201 for knee osteoarthritis, which has Phase 1 data and is in Phase 2 development with RMAT and ATMP designations. It also acquired the remaining stake in GQ Bio Therapeutics and licensed PCRX-2002 from AmacaThera.
The filing describes extensive clinical data supporting EXPAREL, ZILRETTA and iovera°, the IGOR real‑world outcomes registry, manufacturing capacity with Thermo Fisher and internal facilities, and key commercial agreements. It also notes a Paragraph IV settlement that allows limited generic EXPAREL entry starting in early 2030 and a favorable royalty dispute judgment requiring RDF to repay $23.1 million plus $5.2 million interest.